Harvard Scientist Wins £50k Lush Prize for Cervix‑Vagina Organ‑on‑Chip

Women’s health receives a small share of public research money. Only 2% of funding goes to pregnancy, childbirth, and female reproductive health, despite women making up half the population. This gap has limited progress on conditions such as infertility and pre‑term birth. The Lush Prize, awarded annually since 2012, recognises scientists who develop alternatives to animal testing. On 12 May in London, Dr Izadifar will accept the £50,000 award for her work on organ‑on‑chip models of the female reproductive tract.

Dr Izadifar’s team built a microfluidic device the size of a fingertip that contains living human cervical and vaginal epithelial cells. The chip is equipped with micro‑sensors that measure electrical changes as the cells interact with hormones, beneficial bacteria, and pathogens. According to Dr Izadifar, the platform produced the first human cervix and vagina organ‑on‑chip models that accurately replicate tissue function and responses to hormonal shifts, microbiome changes, and infection challenges. The validation used primary cells from several donors; the exact sample size was not disclosed in the public announcement. Because the system relies on human cells, observations show correlations between hormone exposure and altered barrier function, but the chip alone does not prove causation for clinical outcomes. Further studies will be needed to link chip responses to disease mechanisms in vivo.

The technology offers a path to reduce reliance on animal models, which often fail to mimic human menstruation, menopause, or vaginal microbiome processes. By providing a reproducible human‑based platform, researchers can screen drugs, study infection dynamics, and explore infertility factors more efficiently. Regulatory agencies are increasingly accepting organ‑on‑chip data for safety testing, suggesting the cervix‑vagina chip could accelerate preclinical evaluation while meeting ethical standards. Researchers caution that scaling the chip for high‑throughput screening and integrating it with clinical data remain challenges. Future work will focus on long‑term culture stability and multi‑organ linking to model systemic effects. Watch for upcoming peer‑reviewed publications detailing chip performance in hormone therapy and antimicrobial testing, and for any pilot studies that attempt to correlate chip readouts with patient outcomes.